Samsung Acquires NeuroLogica
- Samsung plans expansion into the medical device sector
- Computer giant acquires NeuroLogica as part of its expansion
Samsung has announced its acquisition of medical imaging company NeuroLogica. The technology giant plans to build a leading medical technology business and “the acquisition of NeuroLogica is another important step in the expansion of Samsung’s medical imaging business,” said Tod Pike, Senior VP at Samsung’s Enterprise Division.
The press statement outlines Samsung’s plans to expand its medical division, however terms of the deal itself were not disclosed.
NeuroLogica was founded in 2004 in Boston and it known for its portable computed tomography (CT) scanners, including BodyTom and CereTom.
Samsung has outlined ambitious plans to become one of the world’s leading medical equipment suppliers by 2020.
In November 2012, Samsung Electronics America, a subsidiary of Samsung, announced the addition of Samsung Health & Medical Equipment, which merged employees from Samsung Medison America, its ultrasound machine manufacturer, into its Enterprise Business Division.
Samsung had acquired Medison in 2010 and its medical technology business as a “key element in Samsung’s 2020 vision to explore new areas of growth,” said the company at the time.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”